Arne Kristian
Arne Kristian Dahle, Kenmore Hills AU
Patent application number | Description | Published |
---|---|---|
20090297394 | ALUMINIUM CASTING ALLOY - A method of forming a hypoeutectic aluminium silicon alloy including the steps of: forming an aluminium melt including greater than zero and less than about 12 wt % silicon, adding 20-3000 ppm of a eutectic modifying element selected from the group consisting of strontium, sodium, antimony, barium, calcium, yttrium, lithium, potassium, ytterbium, europium and mischmetal; and either adding nucleant particles and/or causing nucleant particles to be formed in the melt, the nucleant particles being selected from the group of TiSix, MnCx, AlP, AlBx and CrBx wherein x is an integer of 1 or 2. | 12-03-2009 |
Arne Kristian Dahle, Queensland AU
Patent application number | Description | Published |
---|---|---|
20090123325 | Magnesium Alloys For Hydrogen Storage - A method of producing a hydrogen storage material including the steps of: forming a magnesium-nickel melt having up to 50 wt % nickel; adding up to 2 wt % of a refining element to the melt under a non-oxidising atmosphere, the refining element having an atomic radius within the range of 1-1.65 times the atomic radius of magnesium, such as at least one element selected from the group consisting of Zr, Na, K, Ba, Ca, Sr, La, Y, Yb, Rb and Cs; and solidifying the melt to produce the hydrogen storage material. | 05-14-2009 |
Arne Kristian Nordhei, Olso NO
Patent application number | Description | Published |
---|---|---|
20080261210 | Assay Method - The invention provides a cassette-based automated assay for homocysteine. | 10-23-2008 |
Arne Kristian Nordhei, Oslo NO
Patent application number | Description | Published |
---|---|---|
20140302540 | BLOOD SAMPLE ASSAY METHOD - The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component. The method includes: i) diluting the sample with a reagent mixture; ii) substantially removing blood cells; iii) using a reagent which serves to temporarily prevent reaction of the second component, to generate a blocked second component; iv) causing the selective reaction of a constituent of each analyte to directly or indirectly generate detectable reaction products, where one of the analytes is the first component; v) monitoring the detectable reaction product or products; vi) relating an amount of the detectable product or products and/or a rate of formation of the detectable product or products to the concentration of each analyte, where the concentration of at least the first component is related to a corresponding detectable reaction product by means of estimating an un-measurable (fictive) endpoint. Step iii) may be carried out at any stage up to and including step iv) but before steps v) or vi). The reagent of step iii) may be applied to the sample separately or may be included in a reagent mixture during steps i) or iv). A corresponding kit is also provided. | 10-09-2014 |